Travere Therapeutics (TVTX) earnings

Earnings (net income) · fiscal 2025
-$25.55M

Travere Therapeutics (TVTX) reported net income of -$25.55M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$321.55M. Figures as of 18 Nov 2026, 07:10 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
-$25.55M
Highest on record
$117.24Mfiscal 2015
Lowest on record
-$321.55Mfiscal 2024
Fiscal years on record
162011–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Travere Therapeutics earnings, in more detail

Across the 16 fiscal years on record (2011–2025), the highest was $117.24M in fiscal 2015 and the lowest -$321.55M in fiscal 2024.

History · 16 fiscal years

Earnings (net income) by fiscal year

Travere Therapeutics earnings, year by year

Travere Therapeutics (TVTX) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025-$25.55M—
2024-$321.55M—
2023-$111.40M—
2022-$278.48M—
2021-$180.09M—
2020-$169.43M—
2019-$146.43M—
2018-$102.68M—
2017-$59.73M—
2016-$47.90M 140.9% down
2015$117.24M—
2014-$110.94M—
2013-$34.63M—
2012-$30.34M—
2012-$14.83K—
2011-$23.02K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Travere Therapeutics and comparable companies
CompanyEarnings (net income)Fiscal year
MiniMed Group MMED-$333.00M2026
Adaptive Biotechnologies ADPT-$59.50M2025
Heartflow HTFL-$116.79M2025
CRISPR Therapeutics CRSP-$581.60M2025
Travere Therapeutics TVTX-$25.55M2025
Option Care Health OPCH$207.59M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TVTX

Travere Therapeutics, figure by figure

Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value

Travere Therapeutics earnings: questions and answers

What is Travere Therapeutics's net income?

Travere Therapeutics (TVTX) reported net income of -$25.55M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$321.55M.

What are the highest and lowest net income figures on record for Travere Therapeutics?

Across the 16 fiscal years on record (2011–2025), the highest was $117.24M in fiscal 2015 and the lowest -$321.55M in fiscal 2024.

How is Travere Therapeutics's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Travere Therapeutics (TVTX) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/TVTX/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.